# Confirmation of ProMisE: a genomics-based clinical classifier for endometrial cancer

Source: https://onco.cc/key-papers/paper-promise-talhouk-cancer-2017/  
OnCo record `paper-promise-talhouk-cancer-2017` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The ProMisE classifier uses three tests, mismatch repair and p53 immunohistochemistry plus POLE sequencing, to sort endometrial cancers into four molecular groups that reproduce the Cancer Genome Atlas subtypes and predict outcome.

## Summary

Confirmation study in 319 endometrial cancers of the Proactive Molecular Risk Classifier for Endometrial Cancer, assigning tumours to POLE-mutated, mismatch repair-deficient, p53-abnormal or p53 wild-type (no specific molecular profile) groups using immunohistochemistry and targeted sequencing.

The classifier was reproducible, could be applied to biopsy material and stratified survival, with POLE tumours faring best and p53-abnormal worst, independent of traditional risk factors.

## Fields

- Kind: Key paper
- Last checked: 2026-09-17
- Journal: Cancer
- Year: 2017
- DOI: 10.1002/cncr.30496
- Authors: Talhouk A, McConechy MK, Leung S, et al.
- Findings: Four molecular groups with distinct survival; p53-abnormal worst, POLE best.; Classifier reproducible on diagnostic biopsies with high concordance to hysterectomy specimens.
- What it means: Molecular classification of every endometrial cancer, now embedded in the WHO classification and the ESGO/ESTRO/ESP guideline, rests on ProMisE; it decides adjuvant therapy and identifies candidates for immunotherapy.
- Caveats: Tumours with more than one classifying feature (multiple classifiers) need hierarchical assignment rules.; POLE sequencing is not yet universally available.

## Sources

- Cancer 2017: https://doi.org/10.1002/cncr.30496
- PubMed: https://pubmed.ncbi.nlm.nih.gov/28061006/

## Connected records

- cancers: [Endometrial cancer with no specific molecular profile](https://onco.cc/cancers/endometrial-nsmp/), [Mismatch-repair-deficient endometrial cancer](https://onco.cc/cancers/endometrial-mmr-deficient/), [p53-abnormal endometrial cancer, including uterine serous carcinoma](https://onco.cc/cancers/endometrial-p53-abnormal/), [POLE-ultramutated endometrial cancer](https://onco.cc/cancers/endometrial-pole-ultramutated/)
- journals: [Cancer](https://onco.cc/journals/cancer-wiley/)

---
JSON: https://onco.cc/api/v1/entities/paper-promise-talhouk-cancer-2017.json